Lusvertikimab & the Future of IBD: KOL Insights Post-ECCO

Save the date and join OSE Immunotherapeutics on 5 March at 6pm CET | 12pm ET for an exclusive webinar featuring top key opinion leaders (KOLs) and industry experts on the latest scientific and clinical highlights from ECCO 2025, with a focus on lusvertikimab (OSE-127) and advancements in the treatment of inflammatory bowel disease (IBD).